133 related articles for article (PubMed ID: 31270017)
1. Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
Kang JS; Lee J; Nam LB; Yoo OK; Pham KT; Duong TH; Keum YS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2189-2196. PubMed ID: 31270017
[TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
[TBL] [Abstract][Full Text] [Related]
3. TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment.
Guo S; Bai X; Shi S; Deng Y; Kang X; An H
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681590
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis.
Mi R; Zhao J; Chen L; Wei X; Liu J; Wei X
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e752-e767. PubMed ID: 34301487
[TBL] [Abstract][Full Text] [Related]
5. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Novotny L; Al-Tannak NF; Hunakova L
Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.
Kantarjian HM; O'Brien S; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):530-3. PubMed ID: 23790799
[TBL] [Abstract][Full Text] [Related]
7. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
8. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine deregulates
Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy.
Zhang Y; Huang N; Xu J; Zheng W; Cui X
Drug Des Devel Ther; 2020; 14():4749-4763. PubMed ID: 33177810
[TBL] [Abstract][Full Text] [Related]
13. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
14. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
16. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine.
Howard TP; Oberlick EM; Rees MG; Arnoff TE; Pham MT; Brenan L; DoCarmo M; Hong AL; Kugener G; Chou HC; Drosos Y; Mathias KM; Ramos P; Seashore-Ludlow B; Giacomelli AO; Wang X; Freeman BB; Blankenship K; Hoffmann L; Tiv HL; Gokhale PC; Johannessen CM; Stewart EA; Schreiber SL; Hahn WC; Roberts CWM
Clin Cancer Res; 2020 Sep; 26(18):4995-5006. PubMed ID: 32631955
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine: history, current research, and future direction.
Kantarjian HM; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien SM
Cancer; 2001 Sep; 92(6):1591-605. PubMed ID: 11745238
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application.
Wu Q; Chen P; Li J; Lin Z; Zhang Q; Kwok HF
Pharmacol Res; 2023 Feb; 188():106654. PubMed ID: 36640858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
